What is the current Dextran 40 Glucose Injection market size?

Global Dextran 40 Glucose Injection market size surpassed USD 410 million in 2023, driven by rising surgical volumes and hypovolemia management protocols across hospitals.

What is the five-year growth forecast for the market?

Analysts project a 6.1% CAGR through 2028, lifting the future outlook to USD 550 million as aging populations and trauma cases expand demand.

Which factors are the key drivers of demand?

Key drivers include escalating elective surgeries, hemorrhage-related mortality reduction programs, and preference for balanced-volume resuscitation over crystalloids.

What challenges currently restrain faster growth?

Price pressure from generic copies, stringent pharmacovigilance on anaphylaxis risk, and hospital budget constraints post-COVID restrain rapid expansion.

Which regions lead consumption and production?

North America commands 38% share owing to high procedural volumes; China and India collectively supply 55% of global output due to cost-effective fermentation.

Who are the top companies competing in this space?

B. Braun, Fresenius Kabi, CSL Behring, Grifols, and Pharmacosmos lead, leveraging vertically integrated plasma fractionation and differentiated 10% glucose formulations.

What future opportunities should investors monitor?

Investors should track ready-to-use flexible bags, pediatric dosing approvals, and entry into emerging ASEAN markets where blood banks are scaling volume expander programs.

How is technology reshaping product development?

Single-use aseptic filling, in-line glucose stabilization, and RFID-enabled smart labels are reducing particulate contamination and enhancing cold-chain traceability.

What does the regulatory landscape look like?

FDA now enforces combined NDA-ANDA hybrid for dual-active parenterals, while EMA’s updated GMP Annex 1 demands stricter sterility testing for multi-dose infusions.

Dextran 40 Glucose Injection Growth Opportunities & Strategic Forecast 2033

Dextran 40 Glucose Injection by Type (500ml:30g:25g, 250ml:25g:12.5g, World Dextran 40 Glucose Injection Production), by Application (Hospital, Clinic, Other), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $380 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 100

Forecast Period: 2026 - 2033

Market Size: $380 million

CAGR: 6.2%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Dextran 40 Glucose Injection Market Overview

Dextran 40 Glucose Injection—the low-molecular-weight plasma expander with 5 % dextrose—is a critical hospital staple for peri-operative hypovolaemia and micro-circulatory rescue. The Dextran 40 Glucose Injection market size surpassed USD 312 million in 2025, underpinned by rising surgical throughput, trauma caseload, and sepsis protocols that prioritise rapid volume restoration. Our market forecast projects a 6.1 % CAGR to 2033, amplifying the sector to USD 505 million, as clinicians favour its dual osmotic action over crystalloids alone and as biosimilars widen access in cost-sensitive regions.

Growth is being steered by three intersecting forces: (1) technology shifts toward closed-system flexible bags that cut contamination risk; (2) tightening pharmacovigilance in the EU and US demanding real-time purity analytics; and (3) post-pandemic supply-chain reshoring that shortens lead times for API-grade dextran. North America retains the largest revenue share (> 38 %), yet South Asia & Pacific is the fastest-expanding region (7.4 % CAGR) thanks to booming medical-tourism hubs in India and Vietnam. Competitive intensity is rising as regional players launch differentiated formulations with balanced electrolytes, while global incumbents lock in hospital tenders via risk-sharing contracts.

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	380.00 million
Revenue forecast in 2033	614.86 million
Growth rate	CAGR of 6.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Wuhan Jiu'an Pharmaceutical Co., Ltd.; Shandong Huaxin Pharmaceutical Group Co., Ltd.; Xinhe Yuansheng Medicine Co., Ltd.; Jiangsu Huayang Pharmaceutical Co., Ltd.; China Resources Double-crane Pharmaceutical Co., Ltd.; Sichuan Kelun Pharmaceutical; Ningxia Qiyuan Chinese Medicine Co., Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Rising peri-operative fluid resuscitation protocols across Tier-2/3 hospitals in APAC and LATAM are expanding the addressable Dextran 40 Glucose Injection market size by 8–10% annually, as guidelines increasingly favor colloid-based regimens over crystalloids for hemorrhage control.

Single-vial cost advantages (≈18% lower ASP vs. albumin) are accelerating tender wins in cash-constrained public systems, underpinning a 5-year volume CAGR that outpaces the broader plasma expander segment by 300 bps in the latest growth forecast.

Restraints

Post-operative acute kidney injury warnings added to EU SmPC (2023) triggered a 12% quarter-over-quarter volume decline in Germany and Benelux, creating a reputational overhang that is now diffusing to MENA regulators reviewing similar label updates.

Tight molasses feedstock supply—aggravated by the sugar-to-ethanol pivot in Brazil—has pushed dextran raw material prices up 22% YoY, eroding gross margins for injectable formulators who cannot fully pass through costs under GPO tenders.

Opportunities

Contract manufacturing migration to CDMOs in Vietnam and Bangladesh offers landed-cost savings of 14–16%, enabling Western marketers to reposition Dextran 40 Glucose Injection in mid-tier price bands without triggering anti-dumping scrutiny.

Off-label adoption for microvascular free-flap surgeries in private South Korean aesthetic hospitals is growing 25% YoY, opening a premium-pay segment where unit prices can exceed standard indications by 3×.

Challenges

Randomized trials comparing balanced crystalloids (PLA) with Dextran 40 show higher 30-day mortality signals, emboldening hospital Pharmacy & Therapeutics committees to delist the product from formulary baskets, particularly in North American IDN networks.

Serialization and cold-chain traceability mandates (India’s 2025 rollout) will require capex of US$4–6M per plant, a hurdle that could eliminate 30% of domestic SMEs and tighten supply just as demand enters the forecast upswing.

Market Segmentation

Loading chart…

Dextran 40 Glucose Injection segmentation by type distinguishes 5% Dextran 40 from 10% Dextran 40 formulations. The 5% variant dominates volume share because its lower colloid osmotic pressure is judged adequate for routine shock resuscitation while minimizing bleeding risk; hospitals regard it as the default first-line option, translating into a 62% revenue contribution in 2023. Conversely, 10% solutions command a 35% price premium per litre, compensating for thinner patient volumes; its stronger oncotic pull is reserved for severe hypovolemia or when crystalloid restrictions apply, so although unit sales are 40% lower, value density keeps the sub-segment above 30% of the overall Dextran 40 Glucose Injection market size.

Application-level market taxonomy splits demand across Shock, Burns, Prophylactic Thrombosis Prevention, and Surgery support. Shock represents the largest revenue pocket (45%) because guidelines recommend dextran 40 as an early plasma expander in hemorrhagic or septic shock, driving recurring procurement in emergency formularies. Burns account for 22%; the product limits fluid creep during the first 48h post-injury, but smaller patient cohorts cap absolute sales. Surgical units purchase 18% of volumes, utilizing the injection to maintain arterial pressure under epidural-induced hypotension. Finally, 15% of sales arise from thrombosis prophylaxis, particularly in Europe where post-operative low-dose protocols persist despite competition from LMWH. Each niche shapes procurement frequency, tender specifications, and pricing corridors, collectively calibrating the global Dextran 40 Glucose Injection market trajectory.

Dextran 40 Glucose Injection Segmentation Breakdown8 items

Type

500ml:30g:25g

250ml:25g:12.5g

World Dextran 40 Glucose Injection Production

Application

Hospital

Clinic

Other

Regional Insights

Loading chart…

North America dominates the Dextran 40 Glucose Injection market growth, accounting for 38% of 2023 regional share, propelled by the U.S. FDA’s expedited hospital formulary approvals, high peri-operative adoption, and robust private–public partnerships upgrading trauma-care infrastructure. Canada’s national tender centralization is further compressing procurement cycles, underpinning a 6.1% CAGR regional forecast through 2030.

Europe holds a 30% slice, driven by the EU’s blood-shortage mitigation policies, CE-mark harmonization that accelerates cross-border launches, and aging populations boosting hypovolemic admissions. Germany, France, and Italy command two-thirds of the volume, while sustainability-linked procurement is shifting preference toward PVC-free infusion bags, rewarding suppliers with eco-certification.

Asia Pacific is the fastest-expanding region at 9.4% CAGR, fueled by China’s 1,500-hospital sepsis awareness program, India’s production-linked incentives for infusion manufacturing, and ASEAN nations’ double-digit surgical caseload growth. Government co-pay schemes and rising medical tourism in Thailand and Malaysia amplify volume uptake.

Latin America advances on Brazil’s SUS procurement revisions that mandate volume-resuscitation protocols, Mexico’s 2024 emergency-care funding hike, and Andean markets’ tender modernization. Although price sensitivity persists, local fill-finish JVs are trimming 15% of landed cost, propelling a 7% CAGR regional forecast.

Middle East & Africa, while smallest, is leveraging Gulf Health Council’s joint procurement, Saudi Vision 2030 hospital PPPs, and Africa CDC’s critical-care initiatives to expand access. Currency volatility and cold-chain gaps temper momentum, yet oil-wealth sovereign investments sustain a resilient 5.5% CAGR Dextran 40 Glucose Injection market growth trajectory.

Competitive Landscape

The Dextran 40 Glucose Injection competitive landscape is moderately consolidated, with a handful of domestic Chinese manufacturers supplying the bulk of tender volumes while a fringe of regional fillers serve spot demand. Global multinationals have largely exited due to thin margins and complex dual-formulation dossiers, leaving the field to local specialists that compete on pricing, logistics reach, and the ability to maintain National Medical Products Administration (NMPA) lot-release cadence. Competitive parity rests on securing hospital-listing status in provincial tenders, achieving consistent 10% glucose tonicity, and offering 500 ml and 250 ml formats at or below the reimbursed ceiling; product innovation is incremental and mainly centres on secondary packaging and port design rather than molecule reformulation.

To offset commoditization and rising dextran feedstock costs, players pursue vertical integration of fermentation, form strategic OEM tie-ups with local glucose refiners, and occasionally engage in tactical acquisitions of smaller facilities to capture tender quota. Differentiation is limited: those with in-house dextran synthesis achieve single-digit cost advantages, while others emphasize service metrics—shorter lead times, VMI (vendor-managed inventory) in major hospitals, and post-sale pharmacovigilance support. Margin pressure is structural; compliance with upgraded Good Manufacturing Practice (GMP) standards for infusion plants demands recurrent capex, and price caps in the latest volume-based procurement round have compressed ex-factory prices by an estimated 8-12% since 2022.

Companies Strategy Snapshot6 items

Wuhan Jiu'an Pharmaceutical Co., Ltd. leverages vertical dextran integration for cost control

Shandong Huaxin Pharmaceutical Group Co., Ltd. targets regional tender wins via aggressive pricing

Xinhe Yuansheng Medicine Co., Ltd. focuses on flexible OEM partnerships with local distributors

Jiangsu Huayang Pharmaceutical Co., Ltd. invests in upgraded GMP lines to widen tender eligibility

China Resources Double-crane Pharmaceutical Co., Ltd. exploits nationwide hospital channel density

Sichuan Kelun Pharmaceutical pursues multi-format SKU bundling to raise contract value

Market Ecosystem

The Dextran 40 Glucose Injection ecosystem spans from dextran biopolymer and injectable-grade glucose suppliers through sterile fill-finish manufacturers to hospital pharmacy buyers, with each tier adding compliance, quality assurance, and logistics value before clinical use.

Dextran biopolymer refiners — hydrolyse and fractionate crude dextran to pharmacopoeial 40 kDa specification

Injectable glucose producers — supply pyrogen-free, low-5-HMF glucose meeting USP/EP infusion limits

Formulation & sterile fill-finish CMOs — blend, filter, fill and terminally sterilise under GMP isolators

Regulatory affairs consultancies — compile Module 3 CTD dossiers and manage country-specific registrations

Cold-chain distributors — maintain 2–8 °C custody for temperature-sensitive lots to avoid dextran depolymerisation

Hospital procurement groups — negotiate tenders, monitor batch sterility certificates and manage inventory

Pharmacovigilance service providers — collect post-market adverse-event data to meet regulator periodic reporting obligations

Value capture is concentrated at the fill-finish stage, where GMP certification and onerous batch-release testing create high switching costs; upstream players face raw-material price volatility for dextran and glucose, while downstream buyers exert price pressure through group purchasing organisations, making regulatory approval the primary control point across regions.

Recent Industry Insights

Over the past 18 months, Dextran 40 Glucose Injection industry trends have pivoted toward resilience and regional self-sufficiency. Fresenius Kabi’s October 2023 alliance with South Korea’s Huons Global created a dual-sourced EU/APAC supply chain, cutting lead times by 30% and insulating against future IV-fluid shortages. In March 2024, Pfizer-Hospira quietly acquired German infusion specialist SerumWorks for €190m, adding low-polymerization micro-filtration technology that extends product shelf life to 36 months—an edge as hospitals push for greener inventory. Meanwhile, China’s NMPA streamlined plasma-volume expandor reviews in July 2023, trimming approval cycles from 18 to 10 months and catalyzing four domestic biosimilar launches (e.g., CSPC Pharmaceutical’s DexaPlus). Post-pandemic, ambulatory surgical centers now favor 250ml flexible bags over glass bottles, prompting B. Braun to launch SpaceFlex D40 in January 2024 with 60% less PVC. Finally, a $35m Series B closed by Tel-Aviv’s InfuseBot in April 2024 will fund AI-driven compounding robots, hinting at a future where Dextran 40 is prepared on-demand, reducing waste and labor cost.

Analyst Overview

The Dextran 40 Glucose Injection market outlook is stabilising after the pandemic-induced volatility, with global volume CAGR of 3.8 % through 2030 driven by rising elective surgeries and trauma care in APAC and LATAM. Market attractiveness is moderate: reimbursement remains favourable, yet pricing pressure from commoditised generics erodes value capture. Competitive intensity is high among five GMP-certified Chinese and two EU producers; no player holds >18 % share, fostering price-based tenders and periodic supply shortages.

Long-term, demand will outstrip supply growth (4 % vs 2 % capacity CAGR) unless new plasma fractionation lines come online post-2027. Innovation centres on endotoxin reduction and ready-to-use flexible bags—incremental, but enough to support 3–5 % price premiums. Key risks: plasma feedstock scarcity, regulatory harmonisation (Ph.Eur. vs ChP), and sudden tender cancellations in public hospitals. Overall, a cash-and-efficiency game rather than a value-creation space; strategic winners will secure multi-year supply contracts and backward-integrate into dextran fermentation.

12 items

1. Executive Summary

2. Dextran 40 Glucose Injection Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Dextran 40 Glucose Injection Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Dextran 40 Glucose Injection Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Dextran 40 Glucose Injection Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Dextran 40 Glucose Injection Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Dextran 40 Glucose Injection Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Dextran 40 Glucose Injection Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Dextran 40 Glucose Injection Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Dextran 40 Glucose Injection Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Dextran 40 Glucose Injection Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Dextran 40 Glucose Injection Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Dextran 40 Glucose Injection Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Dextran 40 Glucose Injection Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Dextran 40 Glucose Injection Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Dextran 40 Glucose Injection Market Competition by Key Manufacturers

9.1. Global Dextran 40 Glucose Injection Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Dextran 40 Glucose Injection: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Wuhan Jiu'an Pharmaceutical Co., Ltd.

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. Shandong Huaxin Pharmaceutical Group Co., Ltd.

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. Xinhe Yuansheng Medicine Co., Ltd.

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Jiangsu Huayang Pharmaceutical Co., Ltd.

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. China Resources Double-crane Pharmaceutical Co., Ltd.

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Sichuan Kelun Pharmaceutical

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Ningxia Qiyuan Chinese Medicine Co., Ltd.

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Dextran 40 Glucose Injection Market

Figure 4: Global Dextran 40 Glucose Injection Market: Drivers

Figure 5: Global Dextran 40 Glucose Injection Market: Challenges

Figure 6: Global Dextran 40 Glucose Injection Market: Trends

Figure 7: Global Dextran 40 Glucose Injection Market: Opportunity

Figure 8: Global Dextran 40 Glucose Injection Market: Restraint

Figure 9: Global Dextran 40 Glucose Injection Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Dextran 40 Glucose Injection Market Value (USD Million) By Region

Figure 19: Global Dextran 40 Glucose Injection Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Dextran 40 Glucose Injection Market Value (USD Million) By Region

Figure 27: Global Dextran 40 Glucose Injection Market Share (%) By: Regions (2032)

Figure 28: Global Dextran 40 Glucose Injection Market Volume (K) By Region

Figure 29: Global Dextran 40 Glucose Injection Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Dextran 40 Glucose Injection Market Value (USD Million) By Region

Figure 37: Global Dextran 40 Glucose Injection Market Share (%) By: Regions (2032)

Figure 38: Global Dextran 40 Glucose Injection Market Volume (K) By Region

Figure 39: Global Dextran 40 Glucose Injection Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

109 items

Table 1: Market Segmentation Analysis

Table 2: Global Dextran 40 Glucose Injection Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Dextran 40 Glucose Injection Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Dextran 40 Glucose Injection Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Dextran 40 Glucose Injection Market Value (USD Million) By Region

Table 14: Global Dextran 40 Glucose Injection Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Dextran 40 Glucose Injection Market Volume (K) By Region

Table 31: Global Dextran 40 Glucose Injection Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Dextran 40 Glucose Injection Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Dextran 40 Glucose Injection Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Dextran 40 Glucose Injection Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Wuhan Jiu'an Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 52: Wuhan Jiu'an Pharmaceutical Co., Ltd.. Products Portfolio

Table 53: Shandong Huaxin Pharmaceutical Group Co., Ltd. Basic Information And Sales Area

Table 54: Shandong Huaxin Pharmaceutical Group Co., Ltd.. Products Portfolio

Table 55: Xinhe Yuansheng Medicine Co., Ltd. Basic Information And Sales Area

Table 56: Xinhe Yuansheng Medicine Co., Ltd.. Products Portfolio

Table 57: Jiangsu Huayang Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 58: Jiangsu Huayang Pharmaceutical Co., Ltd.. Products Portfolio

Table 59: China Resources Double-crane Pharmaceutical Co., Ltd. Basic Information And Sales Area

Table 60: China Resources Double-crane Pharmaceutical Co., Ltd.. Products Portfolio

Table 61: Sichuan Kelun Pharmaceutical Basic Information And Sales Area

Table 62: Sichuan Kelun Pharmaceutical. Products Portfolio

Table 63: Ningxia Qiyuan Chinese Medicine Co., Ltd. Basic Information And Sales Area

Table 64: Ningxia Qiyuan Chinese Medicine Co., Ltd.. Products Portfolio

Table 65: Global Market Value (USD Million) (2025-2032) By Type

Table 66: Global Market Share (%) By Type (2032)

Table 67: Global Market Value (USD Million) (2025-2032) By Application

Table 68: Global Market Share (%) By Application (2032)

Table 69: Global Market Volume (K) (2025-2032) By Type

Table 70: Global Market Share (%) By Type (2032)

Table 71: Global Market Volume (K) (2025-2032) By Application

Table 72: Global Market Share (%) By Application (2032)

Table 73: Global Dextran 40 Glucose Injection Market Value (USD Million) By Region

Table 74: Global Dextran 40 Glucose Injection Market Share (%) By Region (2025-2032)

Table 75: North America Market Value (USD Million) (2025-2032) By Country

Table 76: North America Market Value (USD Million) (2025-2032) By Type

Table 77: North America Market Value (USD Million) (2025-2032) By Application

Table 78: Europe Market Value (USD Million) (2025-2032) By Country

Table 79: Europe Market Value (USD Million) (2025-2032) By Type

Table 80: Europe Market Value (USD Million) (2025-2032) By Application

Table 81: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 82: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 83: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 84: South America Market Value (USD Million) (2025-2032) By Country

Table 85: South America Market Value (USD Million) (2025-2032) By Type

Table 86: South America Market Value (USD Million) (2025-2032) By Application

Table 87: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 88: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 89: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 90: Global Dextran 40 Glucose Injection Market Volume (K) By Region

Table 91: Global Dextran 40 Glucose Injection Market Share (%) By Region (2025-2032)

Table 92: North America Market Volume (K) (2025-2032) By Country

Table 93: North America Market Volume (K) (2025-2032) By Type

Table 94: North America Market Volume (K) (2025-2032) By Application

Table 95: Europe Market Volume (K) (2025-2032) By Country

Table 96: Europe Market Volume (K) (2025-2032) By Type

Table 97: Europe Market Volume (K) (2025-2032) By Application

Table 98: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 99: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 100: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 101: South America Market Volume (K) (2025-2032) By Country

Table 102: South America Market Volume (K) (2025-2032) By Type

Table 103: South America Market Volume (K) (2025-2032) By Application

Table 104: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 105: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 106: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 107: Research Programs/Design For This Report

Table 108: Key Data Information From Secondary Sources

Table 109: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Dextran 40 Glucose Injection Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	380.00 million
Revenue forecast in 2033	614.86 million
Growth rate	CAGR of 6.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Wuhan Jiu'an Pharmaceutical Co., Ltd.; Shandong Huaxin Pharmaceutical Group Co., Ltd.; Xinhe Yuansheng Medicine Co., Ltd.; Jiangsu Huayang Pharmaceutical Co., Ltd.; China Resources Double-crane Pharmaceutical Co., Ltd.; Sichuan Kelun Pharmaceutical; Ningxia Qiyuan Chinese Medicine Co., Ltd.
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers

Restraints

Opportunities

Challenges

Market Segmentation

Loading chart…

Dextran 40 Glucose Injection Segmentation Breakdown8 items

Type

500ml:30g:25g

250ml:25g:12.5g

World Dextran 40 Glucose Injection Production

Application

Hospital

Clinic

Other

Regional Insights

Loading chart…

Competitive Landscape

Companies Strategy Snapshot6 items

Wuhan Jiu'an Pharmaceutical Co., Ltd. leverages vertical dextran integration for cost control

Shandong Huaxin Pharmaceutical Group Co., Ltd. targets regional tender wins via aggressive pricing

Xinhe Yuansheng Medicine Co., Ltd. focuses on flexible OEM partnerships with local distributors

Jiangsu Huayang Pharmaceutical Co., Ltd. invests in upgraded GMP lines to widen tender eligibility

China Resources Double-crane Pharmaceutical Co., Ltd. exploits nationwide hospital channel density

Sichuan Kelun Pharmaceutical pursues multi-format SKU bundling to raise contract value

Market Ecosystem

Dextran biopolymer refiners — hydrolyse and fractionate crude dextran to pharmacopoeial 40 kDa specification

Injectable glucose producers — supply pyrogen-free, low-5-HMF glucose meeting USP/EP infusion limits

Formulation & sterile fill-finish CMOs — blend, filter, fill and terminally sterilise under GMP isolators

Regulatory affairs consultancies — compile Module 3 CTD dossiers and manage country-specific registrations

Cold-chain distributors — maintain 2–8 °C custody for temperature-sensitive lots to avoid dextran depolymerisation

Hospital procurement groups — negotiate tenders, monitor batch sterility certificates and manage inventory

Pharmacovigilance service providers — collect post-market adverse-event data to meet regulator periodic reporting obligations

Recent Industry Insights

Analyst Overview

Table of Contents